drugset / Trial / NCT05130021
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.
Timeline
- Start
- 2022-01-31
- Primary completion
- 2022-05-30
- Completion
- 2023-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MAX-40279-01 | Unknown | 50 mg | — |
| Subject | MAX-40279-01 | Unknown | 70 mg | — |
| Subject | Regorafenib | Small molecule | — | — |